Clinical Trials Logo

Clear Cell Sarcoma clinical trials

View clinical trials related to Clear Cell Sarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02390843 Completed - Clinical trials for Renal Cell Carcinoma

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

AflacST1402
Start date: February 2015
Phase: Phase 1
Study type: Interventional

This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded to standard therapy. This study will define toxicity of high dose simvastatin in combination with topotecan and cyclophosphamide and evaluate for cholesterol levels and IL6/STAT3 pathway changes as biomarkers of patient response.

NCT ID: NCT02162732 Completed - Clinical trials for Renal Cell Carcinoma

Molecular-Guided Therapy for Childhood Cancer

Start date: July 8, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup. This technology includes a genomic report based on DNA exomes and RNA sequencing that will be used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer in the future.

NCT ID: NCT01331135 Completed - Clinical trials for Renal Cell Carcinoma

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

Aflac ST0901
Start date: April 2011
Phase: Phase 1
Study type: Interventional

The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy. These treatments can prolong their life but may not offer a long-term cure. This study proposes using a drug called Sirolimus in combination with common chemotherapy drugs to treat patients with recurrent and refractory solid tumors. Sirolimus has been found to inhibit cell growth and to have anti-tumor activity in pediatric solid tumors in previous studies and, therefore, has the potential to increase the effectiveness of the chemotherapy drugs when given together. This study wil investigate the highest dose of Sirolimus that can be given orally with other oral chemotherapy drugs. Cohorts of 2 subjects will be started at the minimum dose. The dose will be increased in the next 2 subjects as long as there were no major reactions in the previous groups. This study will also seek to learn more about the side effects of sirolimus when used in this combination and what effects the drug has on the white cells and the immune system. Successful use of this drug will impact the cancer population greatly by providing an increased chance of survival to those with resistant or recurrent cancers.